InVitae (NVTA) Tops Q1 EPS by 2c

InVitae (NYSE: NVTA) reported Q1 EPS of ($0.64), $0.02 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $10.9 million.

"We are winning the race to scale in our industry," said Sean George, chief executive officer of Invitae. "By providing more affordable genetic testing, we are opening up access for patients to address a wide spectrum of health issues, from rare diseases to common cancers, fueling increased utilization of our expanding platform. Now in-network with a majority of major payers, we expect the rise in demand for Invitae\'s services in the first quarter will translate into significant revenue growth throughout the remainder of the year."

For earnings history and earnings-related data on InVitae (NVTA) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS
• NextPlat Corp (NXPL) Reports Q2 Loss of $0.05